Safety and Efficacy Study of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis Patients

Read full text Summarise with VIRAT
Authors: Shikha Shukla, Nimisha Kakadia
Cited by: 0
References: 8

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Modifying Antirheumatic Drugs (DMARDs) are integral to managing Rheumatoid Arthritis (RA), yet their long-term safety, efficacy, and cost-effectiveness remain under-explored in the Indian population. Objective: To evaluate the safety, efficacy, prescription patterns, medication adherence, quality of life, and costeffectiveness of biological and non-biological DMARDs in RA patients. Methods: This is a prospective, retrospective, open-labeled observational study conducted at two clinical sites in Gujarat, India. A total of 450 RA patients aged 18–75 years were enrolled in the study. Clinical data, lab parameters, and qualityof- life assessments were recorded. Results: Female patients predominated. Most participants were aged 40–50 years with RA duration exceeding 10 years. Hydroxychloroquine and naproxen were the most prescribed drugs. Lab results revealed elevated ESR and CRP. Conclusion: The study provides valuable insight into DMARD usage, safety, efficacy, and prescription trends among Indian RA patients, supporting a shift towards biological DMARDs with monitored cost-effectiveness and improved patient outcomes.

Fields of Study & Subjects

Rheumatoid Arthritis Research and Therapies Autoimmune and Inflammatory Disorders Research Natural Compounds in Disease Treatment

Publication details

Journal / source
International Journal of Drug Delivery Technology
Volume
16
Issue
3s
Publication date
31 March 2026
Language
EN